What is the price target for BLUE stock?
10 analysts have analysed BLUE and the average price target is 8.84 USD. This implies a price increase of 77.87% is expected in the next year compared to the current price of 4.97.
BLUEBIRD BIO INC (BLUE) Forecast, Price Target & Analyst Ratings
NASDAQ:BLUE • US09609G2093
Current stock price
4.97 USD
0 (0%)
At close:
4.99 USD
+0.02 (+0.4%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BLUEBIRD BIO INC (BLUE).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Aug 12, 2025
- Period
- Q2 / 2025
- EPS Estimate
- -$2.64
- Revenue Estimate
- 46.512M
Price Target Details & History
Consensus Price Target and Range
Mean target
$8.84
Upside
+ 77.87%
From current price of $4.97 to mean target of $8.84, Based on 10 analyst forecasts
Low
$8.08
Median
$8.16
High
$10.50
Price Target Revisions
1 Month
20.37%
3 Months
-57.93%
Price Target Summary
10 Wall Street analysts provided a forecast for the next 12 months for BLUE. The average price target is 8.84 USD. This implies a price increase of 77.87% is expected in the next year compared to the current price of 4.97.
The average price target has been revised downward by 57.93% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
76.00%
BLUE was analyzed by 10 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about BLUE.
In the previous month the buy percentage consensus was at a similar level.
BLUE was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-03-31 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-24 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-02-24 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2024-12-31 | Barclays | Maintains | Overweight -> Overweight |
| 2024-11-15 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-11-15 | Barclays | Maintains | Overweight -> Overweight |
| 2024-11-15 | B of A Securities | Downgrade | Buy -> Neutral |
| 2024-09-25 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Neutral |
| 2024-08-15 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-08-15 | Barclays | Maintains | Overweight -> Overweight |
| 2024-08-15 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2024-08-15 | Baird | Maintains | Outperform -> Outperform |
| 2024-08-15 | B of A Securities | Maintains | Buy -> Buy |
| 2024-03-27 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-03-27 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2024-03-19 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-03-05 | HSBC | Maintains | Reduce -> Reduce |
| 2023-12-21 | B of A Securities | Maintains | Buy -> Buy |
| 2023-12-15 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2023-12-12 | Baird | Maintains | Outperform -> Outperform |
| 2023-12-11 | B of A Securities | Maintains | Buy -> Buy |
| 2023-12-08 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2023-11-08 | Raymond James | Maintains | Outperform -> Outperform |
| 2023-10-17 | Cantor Fitzgerald | Initiate | Neutral |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Aug 12, 2025
- Period
- Q2 / 2025
- EPS Estimate
- -$2.64
- Revenue Estimate
- 46.512M
- Revenue Q2Q
- 188.88%
- EPS Q2Q
- 68.58%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
-27.13%
Revenue (3 Months)
-27.13%
EPS (1 Month)
-53.70%
EPS (3 Months)
-85.69%
Next Earnings Summary
BLUE is expected to report earnings on 8/12/2025. The consensus EPS estimate for the next earnings is -2.64 USD and the consensus revenue estimate is 46.51M USD.
The next earnings revenue estimate has been revised downward by 27.13% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2025 - 2032
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.6M -1.64% | 29.497M 719.36% | 83.807M 184.12% | 222.3M 165.25% | 258.57M 16.32% | 263.16M 1.78% | 339.66M 29.07% | 423.3M 24.62% | 518.16M 22.41% | 610.98M 17.91% | 672.18M 10.02% | |
| EBITDA YoY % growth | -379.15M 30.49% | -308.667M 18.59% | -206.455M 33.11% | -126.079M 38.93% | -25.5M 79.77% | -10.2M 60.00% | 284.9M 2,893.14% | 266.01M -6.63% | 253.87M -4.56% | N/A | N/A | |
| EBIT YoY % growth | -384.15M 32.02% | -337.192M 12.22% | -267.699M 20.61% | -157.109M 41.31% | -134.796M 14.20% | -100.47M 25.47% | -82.62M 17.77% | -29.58M 64.20% | 67.32M 327.59% | 119.34M 77.27% | 149.94M 25.64% | |
| Operating Margin | -10,670.83% | -1,143.14% | -319.42% | -70.67% | -52.13% | -38.18% | -24.32% | -6.99% | 12.99% | 19.53% | 22.31% | |
| EPS YoY % growth | -93.60 60.34% | -38.00 59.40% | -24.75 34.87% | -11.75 52.54% | -6.92 41.13% | -5.05 26.92% | -1.59 68.52% | -0.47 70.51% | 1.09 332.61% | 1.94 77.57% | 2.43 25.26% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|
| EPS Q2Q % growth | -2.64 68.58% | -1.46 76.51% | -1.28 56.70% |
| Revenue Q2Q % growth | 46.512M 188.88% | 69.666M 556.48% | 71.043M 84.43% |
| EBITDA Q2Q % growth | -40.188M 28.74% | -42.84M -155.47% | -43.86M -277.31% |
| EBIT Q2Q % growth | -45.084M 49.00% | -41.82M 34.77% | -32.64M 10.59% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
21.55%
EPS Next 5 Year
14.65%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
52.44%
Revenue Next 5 Year
41.63%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
25.28%
EBIT Next 5 Year
23.54%
BLUEBIRD BIO INC / BLUE Forecast FAQ
Can you provide the upcoming earnings date for BLUEBIRD BIO INC?
BLUEBIRD BIO INC (BLUE) will report earnings on 2025-08-12, before the market open.
Can you provide the consensus estimates for BLUEBIRD BIO INC next earnings?
The consensus EPS estimate for the next earnings of BLUEBIRD BIO INC (BLUE) is -2.64 USD and the consensus revenue estimate is 46.51M USD.
What is the expected long term growth rate for BLUEBIRD BIO INC (BLUE)?
The expected long term growth rate for BLUEBIRD BIO INC (BLUE) is 52.44%.